How do I hire a part-time CRO for a life sciences company in 2027?

The end-to-end process from need definition to signed agreement

The hiring sequence for a part-time revenue leader in life sciences is different from a generalist fractional search because two of the steps — industry vetting and reference calls — carry most of the risk. Get those wrong and you spend four months paying someone to learn your buyer.

Start with a written need definition, not a job description. Answer three questions on one page: What is currently broken (no pipeline, pipeline that does not convert, a team that has no process, or a forecast nobody trusts)? What does "fixed" look like in numbers? And how many days per month of senior attention will that realistically take? A company with two reps and no CRM discipline needs an operator in the system weekly. A company with a strong VP of Sales who needs board-level revenue architecture needs two days a month. Those are different hires at different prices, and conflating them is the single most common mistake.

Second, translate the need into a scope of work before you talk to anyone. Specify deliverables, not hours: a pipeline audit with a written assessment in week four, a rebuilt qualification framework by week eight, a forecast model the board can read by week twelve. Deliverable-based scopes give you a clean basis for the go/no-go decision at day 90 and remove the awkward conversation about whether someone "really worked" their days.

Third, source candidates through channels where senior operators actually sit — communities, investor and board referrals, and targeted LinkedIn searches rather than open job boards. Fractional executives at this level are rarely applying to postings; they are being referred.

Fourth, screen for industry fit hard and early. A 30-minute first call should surface whether the candidate has personally carried a number selling into hospitals, academic medical centers, pharma, biotech, diagnostics labs, medical device buyers, or contract research organizations. If they have not, the conversation can end politely there regardless of how impressive the rest of the résumé is.

Fifth, run references that are specific rather than ceremonial. Ask the reference to describe one deal the candidate personally unstuck and what the obstacle was. Vague praise is not a reference; a story with a named obstacle is.

Sixth, negotiate scope, days, cash-versus-equity mix, and notice period together rather than sequentially — they trade against each other and negotiating them one at a time costs you leverage.

Seventh, sign a short consulting agreement or SOW with a defined term, a 30-day out clause, clear IP and confidentiality terms, and — for life sciences specifically — whatever compliance paperwork your data environment requires. If the fractional leader will touch systems holding protected health information, your legal team will likely need a business associate agreement in place before day one. Do not treat that as a formality to handle later; it can add two weeks if you start it after the handshake.

The whole sequence typically takes four to eight weeks from need definition to first working day, with the compliance paperwork and reference calls being the usual sources of delay. Companies that compress it below three weeks are usually skipping the industry vetting, which is exactly the step that protects the investment.

Where a part-time revenue leader creates or leaks revenue in life sciences

The value of a fractional CRO in this sector concentrates in a handful of places, and so does the waste. Knowing which is which lets you scope the engagement around the work that actually moves money.

Where the value concentrates. The first is stakeholder mapping. Life sciences purchases rarely have a single decision-maker. A diagnostics instrument sale can involve a lab director who wants the technology, a procurement officer optimizing on price and contract terms, a compliance or quality function that has to sign off on validation, an IT group if there is any data integration, and a finance or capital-committee approval if the purchase crosses a capital threshold. A senior operator who has run these deals builds an influence map per opportunity and assigns an owner to each stakeholder. Companies without that map lose deals to silence — the champion goes quiet and nobody knows who actually stalled it.

The second is forecast discipline over long cycles. When deals take nine to eighteen months, simple stage-based conversion math produces forecasts that are wrong in both directions for quarters at a time. An experienced part-time CRO replaces stage percentages with evidence-based criteria: has the buyer confirmed budget in a named fiscal cycle, has a validation or evaluation protocol been agreed, has legal seen the paperwork, has a compliance review been scheduled. Each of those is a binary fact, not a rep's opinion, and a forecast built on them survives board scrutiny.

The third is qualification. Long cycles punish bad qualification more severely than short ones, because a bad deal consumes a year of a rep's capacity rather than a month. Tightening entry criteria at the top of the funnel usually shrinks reported pipeline in the first 60 days — which is uncomfortable, and which you should expect and brief your board on in advance.

The fourth is capital-equipment and consortium purchasing rhythm. Academic medical centers and large health systems buy on institutional calendars, not on your quarter. A leader who knows those rhythms sequences outreach to align with budget cycles instead of fighting them.

Where revenue leaks instead. The most common leak is a fractional hire who defaults to generic playbooks — high-velocity outbound cadences, aggressive discounting to force a close date, or MQL-to-SQL funnel math borrowed from horizontal software. Applied to a regulated, committee-driven buyer, those tactics do not merely underperform; they can damage credibility with clinical and compliance stakeholders who read urgency tactics as a sign the vendor does not understand their environment.

The second leak is under-scoping. Hiring four days a month to do work that requires twelve produces a leader who is always behind, never in the CRM, and reduced to giving advice the team has no capacity to execute. You pay the retainer and get a monthly opinion.

The third is the orphaned engagement — a fractional CRO with no internal counterpart. If nobody on the full-time team owns implementation between the CRO's working days, every recommendation stalls. Assign a named internal owner, even a junior one, before the engagement starts.

The fourth is misaligned incentives on a long cycle. Commission structures tied to closed revenue inside a six-month fractional term are close to meaningless when deals take a year or more; they push the leader toward whatever can be pulled forward rather than toward building the pipeline that pays out later. Tie variable compensation to leading indicators — qualified pipeline created, forecast accuracy, stage-progression rates — or to a longer-dated equity component instead.

Concrete numbers, ranges, and benchmarks to plan against

Fractional CRO pricing is negotiated per engagement and varies widely by geography, stage, and scope, so treat every figure here as a planning band to test against live quotes rather than a market rate.

Days per month. The dominant structures are advisory at roughly 2–4 days monthly, part-time operational leadership at roughly 8–12 days, and heavy interim coverage at 15–20 days. Above 20 days you are effectively buying a full-time executive on a contract basis and should price it that way. Below two days you are buying an advisor, not a CRO, and should call it that so expectations stay honest.

How the fee is structured. Three models dominate: monthly retainer for a defined day band, day rate billed against actual days used, and hourly for pure advisory. Monthly retainer is usually the right choice for operational engagements because it makes the leader indifferent to whether a given problem takes two hours or six, which is what you want. Day-rate billing invites clock-watching on both sides. Whichever you pick, insist the agreement lists deliverables alongside the time commitment, and specify what happens to unused days — most agreements let a small number roll forward one month and then expire.

Equity. Equity in lieu of cash is common at early stage. Grants for part-time revenue leadership typically fall in fractions of a percent up to low single digits depending on stage, day commitment, and how much cash is being displaced. Whatever the number, nail down four terms in writing: the vesting schedule and whether there is a cliff, what happens on early termination by either side, whether there is any acceleration on a change of control, and the exercise window after the engagement ends. A short post-termination exercise window can quietly make a headline equity number worth very little to the person taking it.

Cash-versus-equity trade. Expect a premium on the cash rate when there is no equity component — the leader is pricing in the absence of upside. Conversely, an early-stage company that offers meaningful equity can often secure a stronger operator at a lower cash burn than the same profile would command on cash alone.

Geography. Most of these engagements run remote or hybrid. Supply of life sciences revenue leadership is concentrated in the established hubs — the Boston/Cambridge cluster, San Diego, the San Francisco Bay Area, and the Research Triangle in North Carolina — plus growing pockets around Philadelphia, Seattle, and Chicago. If your scope requires regular onsite presence, expect a premium for travel time and a smaller candidate pool. Be explicit about onsite expectations in the SOW; "occasional travel" is where disputes start.

Timeline benchmarks. Plan on four to eight weeks to hire, one month for a credible audit and written assessment, months two and three for implementation and coaching, and six to twelve months before pipeline impact is clearly visible in the numbers. Closed revenue attributable to the engagement commonly lands twelve to eighteen months out given typical life sciences cycle lengths. Any candidate promising closed revenue inside two quarters in this sector is either inexperienced or selling.

What to measure at day 90. Do not measure closed revenue — the cycle will not permit it. Measure: qualified pipeline created under the new qualification criteria, stage-conversion rates versus the prior baseline, forecast accuracy against the prior quarter's submitted forecast, average deal cycle length trend, CRM data completeness on required fields, and the existence of documented stakeholder maps on every deal above a set threshold. Those six are all observable in 90 days and all predictive of revenue that closes later.

Term and notice. Typical initial terms run three to twelve months. Thirty days' notice is the common default, with two weeks sometimes acceptable for advisory-only scopes. Get the notice period symmetric — if you can exit on 30 days, so can they, and a one-sided clause tends to signal how the rest of the relationship will go.

Pitfalls specific to this hire and how to avoid them

Hiring pure horizontal software pedigree. The most expensive mistake is hiring an impressive revenue leader whose entire background is horizontal B2B software. The instincts that make someone excellent there — speed, volume, tight cycle compression, aggressive close-plan pressure — map poorly onto a buyer who cannot legally or procedurally move faster. Avoid it by making the first screening question about the buying committee, not about revenue scaled: "Walk me through the last deal you closed where a compliance or quality function had veto power. Who were the people and what unstuck it?" Candidates without regulated-buyer experience cannot answer that question with specifics, and it takes about four minutes to find out.

Confusing a career advisor with an operator. Some candidates have been fractional for their entire career and have never carried a number, managed a full sales organization through a funding round, or owned a forecast they had to defend to a board. Their advice can be genuinely good and still leave you without anyone who can build the thing. Prefer candidates who held full-time CRO or VP Sales roles in life sciences before going fractional, and ask directly how many quarters they personally owned a number.

Skipping the compliance groundwork. If the engagement touches systems containing protected health information or regulated clinical data, the contracting is not just a consulting agreement. Get your legal and compliance teams involved during negotiation rather than after, confirm what data access the role actually requires, and scope system permissions to the minimum needed. Starting this after the offer routinely costs two weeks of a paid engagement.

Under-resourcing the internal side. A part-time leader with no internal counterpart produces recommendations that die in a document. Name an internal owner for implementation before day one — the RevOps lead, a sales operations analyst, or the CEO if the company is small enough. Put that person's name in the SOW.

Letting a bad fit run. The cost of a mediocre engagement is not just the retainer; it is the quarter of revenue leadership you did not get. Build the day-90 decision into the contract as a scheduled review with the six metrics above, and hold it on the calendar even when the engagement feels fine. A scheduled review is far easier to act on than an improvised confrontation.

Treating them as an outside vendor. Access is the difference between a leader and a consultant. Give the fractional CRO a company email address, full CRM access, whatever revenue intelligence and sales engagement tooling the team uses, a standing weekly one-on-one with the CEO, and a seat in the relevant board or leadership meetings. Withholding access and then complaining about lack of impact is a self-inflicted wound.

Overloading the first 90 days. A leader who tries to rebuild the CRM, rewrite messaging, restructure territories, hire two reps, and fix the forecast simultaneously will finish none of them. Pick two priorities for the first quarter, write them down, and defend them against scope creep — including your own.

Believing fast-revenue promises. Any claim of doubling revenue in six months in a sector with nine-to-eighteen-month cycles is a red flag about judgment, not a sign of ambition. Honest operators will tell you pipeline impact takes six to twelve months and closed revenue often twelve to eighteen. That answer is the good answer.

Selection checklist and the decision path

Run every candidate through the same gates in the same order, and stop at the first failure rather than talking yourself past it. The order matters: industry fit is cheapest to test and most predictive, so it goes first.

Gate one — regulated life sciences buyer experience. Have they personally sold into hospitals, health systems, academic medical centers, pharma, biotech, diagnostics, medical device buyers, or CROs? Can they name the organizations and describe the buying committee? Pass or stop.

Gate two — operator depth. Did they hold a full-time revenue leadership role before going fractional? How many quarters did they personally own a number? Have they built a sales process from scratch and hired against it? Pass or stop.

Gate three — long-cycle forecasting. Ask how they forecast a nine-to-eighteen-month cycle and what evidence they require to advance a stage. Strong answers cite verifiable buyer actions. Weak answers cite percentages and rep confidence. Pass or stop.

Gate four — systems fluency. Do they know the tooling your team actually runs — the CRM, its life sciences configurations where relevant, revenue intelligence, and sales engagement platforms — well enough to work inside them rather than only opining about them? Pass or stop.

Gate five — specific references. Two reference calls minimum, each producing at least one concrete story of a deal or process the candidate personally fixed. Pass or stop.

Gate six — scope and terms alignment. Do the days, fee structure, equity terms, notice period, and onsite expectations all land where you need them? Negotiate as a package.

Gate seven — the trial. Sixty to ninety days against written milestones, with the day-90 review already on the calendar.

Write the gates down before you meet anyone. Committees that define criteria after seeing candidates end up rationalizing whoever interviewed best rather than choosing whoever fits the buyer.

Related questions

Should I hire a fractional CRO or a full-time VP of Sales?

Fractional fits when you need senior revenue architecture without a full executive salary, typically at earlier revenue stages. A full-time VP fits when you have a team of five or more reps needing daily management and enough revenue to fund the seat plus benefits and equity.

How long should the first engagement term be?

Three to six months with a 30-day mutual notice clause and a formal day-90 review. That is long enough for a credible audit and implementation, short enough that a poor fit does not consume a year of revenue leadership you cannot get back.

Can a fractional CRO also sit on my board?

It happens, but treat it as two roles with two agreements and disclose the arrangement. A board seat carries fiduciary duties that can conflict with an operating engagement the board itself oversees — particularly when the board votes on that engagement's renewal or compensation.

What should the first 30 days produce?

A written revenue assessment: pipeline quality by stage, qualification gaps, forecast reliability versus history, team capability by rep, systems and data hygiene findings, and a prioritized 90-day plan naming two priorities. If you get slides instead of findings, that is a signal.

Do I need one if I already have a strong VP of Sales?

Sometimes — as advisory rather than operational scope. A two-to-four-day monthly engagement can add board-facing revenue architecture, pricing and packaging input, and coaching for the VP without creating a reporting conflict. Be explicit that the VP still owns the number.

FAQ

What notice period is standard for a part-time CRO engagement?

Thirty days is the common default, with two weeks occasionally acceptable for advisory-only scopes. Insist the clause is symmetric — either party can exit on the same terms. A one-sided notice provision is worth pushing back on, because it usually reflects a broader posture about how the relationship will be governed rather than a real commercial need.

How do I structure variable compensation when deals take over a year to close?

Tie it to leading indicators rather than closed revenue inside the term. Qualified pipeline created under agreed criteria, forecast accuracy against submitted numbers, and stage-progression rates are all measurable within the engagement and predictive of revenue that lands later. Pair that with an equity component if you want alignment past the contract end date.

What if the candidate wants equity and my company is not ready to grant it?

That is a normal negotiation. Many part-time revenue leaders work cash-only, though you should expect a higher cash rate to compensate for the absent upside. Be transparent about why — a cap table you are protecting ahead of a raise is a reason experienced operators understand and will price around rather than walk away from.

Does a fractional CRO need compliance training or agreements before starting?

If the role touches systems holding protected health information or regulated clinical data, almost certainly yes — commonly a business associate agreement plus whatever internal training your compliance function requires of anyone with that access. Start the paperwork during negotiation, not after signing, and scope system permissions to the minimum the work requires.

How many days per month is realistic for a company with two sales reps and no process?

Plan on eight to twelve. Building a qualification framework, cleaning the CRM, sitting in on calls, and coaching two reps is hands-on work that cannot be done in two days a month. If budget only supports four days, narrow the scope to one deliverable — usually the qualification and forecasting framework — rather than spreading four days across everything.

What is the clearest signal in the first 30 days that this is not working?

No written assessment, or an assessment that could describe any company. A strong part-time revenue leader in life sciences will name your specific buying committee, your specific stalled deals, and your specific data gaps by week four. Generic findings mean they have not done the work of understanding your buyer, and that gap does not close on its own.

Sources

• U.S. Food and Drug Administration — device and diagnostics regulatory guidance
• U.S. Department of Health and Human Services — HIPAA business associate guidance
• Harvard Business Review — leadership, hiring, and organizational design
• MIT Sloan Management Review — management and go-to-market research
• Pavilion — community for revenue leaders
• National Institutes of Health — research institution and academic medical center context
• U.S. Bureau of Labor Statistics — occupational outlook for sales managers
• First Round Review — startup leadership and hiring practice

Related on PULSE

• How do I find a fractional CRO in Millsboro in 2027?
• How do I hire a fractional CRO in Tulsa in 2027?
• How do I find a fractional CRO in Oakton in 2027?
• Where do I find an interim CRO in Durham in 2027?
• How do I find a fractional CRO in Montgomery Village in 2027?
• How do I hire a fractional CRO in Charlotte in 2027?